​​​​​​​​​​​​​​​​​​Start up Stadium logo 

3 Phoenix Bio-startups land in global Bio International 2019 Start-Up Stadium

​Changing cancer from life-ending diagnosis to treatable disease moves a step closer to reality if three Phoenix-based bioscience startups find strategic partners or venture capital in the BIO International Startup Stadium, June 3-6, in Philadelphia, Pennsylvania.

Hundreds of bioscience companies from around the world vie for one of the 40 presentation slots in the stadium at the world’s largest gathering of bioscience companies, bio venture capitalists and scientists. Last year, more than 18,000 people attended the conference in Boston. BIO, the Biotechnology Innovation Organization, hosts the world’s largest global conferences for biotechnology and life sciences.

Phoenix bio startups Humabiologics, LLC, Kalos Therapeutics and Ordinatrix LLC will make their pitches in BIO’s Startup Stadium beginning Monday. The BIO 2019 Start-Up Stadium provides early-stage companies the opportunity to access key members of the investment community, venture philanthropy groups, strategic partners, and capital.

Humabiologics LLC, based in the Center for Entrepreneurial Innovation, stretches the gift of human tissue and organ donation by providing researchers with a stable supply of high quality and affordable human-derived biomaterials for translational regenerative therapies. Humabiologics is a regenerative medicine startup founded by scientists and tissue industry experts.

Kalos Therapeutics is developing a non-toxic cancer treatment with little or no side effects. The revolutionary technology leverages a natural, known mechanism in the body to regular cell growth. It works by inhibiting the growth of cancer cells.

Ordinatrix LLC, provides research and development tools that aid in the development of new drugs, diagnosis of disease and approaches to personalized medicine. The company is an innovation spinoff from Arizona State University. It creates or “prints” protein microarrays based on DNA. The protein arrays deliver more functional, flexible and precise options for researchers.

Investor judges attend the presentations, pepper company executives with questions. The judges seek answers demonstrating the company has the scientific, human resource and business acumen to succeed. After sessions, judges provide feedback for the finalists. While any of the 40 presenting companies can find strategic partners, grant opportunities or venture investors, five companies designated as the winners receive other key benefits for fuel getting products to approval and market.

To be considered qualified to take the stage at the stadium, companies cannot have raised more than $10 million since inception and employ fewer than 20 full-time employees. The firms must have made a previous business pitch or participated in a capital competition. No previous experience in BIO partnering is permitted.​

​​



3 Phoenix Bio-startups land in global Bio International 2019 Start-Up Stadium

 

​Changing cancer from life-ending diagnosis to treatable disease moves a step closer to reality if three Phoenix-based bioscience startups find strategic partners or venture capital in the BIO International Startup Stadium, June 3-6, in Philadelphia, Pennsylvania.

Hundreds of bioscience companies from around the world vie for one of the 40 presentation slots in the stadium at the world’s largest gathering of bioscience companies, bio venture capitalists and scientists. Last year, more than 18,000 people attended the conference in Boston. BIO, the Biotechnology Innovation Organization, hosts the world’s largest global conferences for biotechnology and life sciences.

Phoenix bio startups Humabiologics, LLC, Kalos Therapeutics and Ordinatrix LLC will make their pitches in BIO’s Startup Stadium beginning Monday. The BIO 2019 Start-Up Stadium provides early-stage companies the opportunity to access key members of the investment community, venture philanthropy groups, strategic partners, and capital.

Humabiologics LLC, based in the Center for Entrepreneurial Innovation, stretches the gift of human tissue and organ donation by providing researchers with a stable supply of high quality and affordable human-derived biomaterials for translational regenerative therapies. Humabiologics is a regenerative medicine startup founded by scientists and tissue industry experts.

Kalos Therapeutics is developing a non-toxic cancer treatment with little or no side effects. The revolutionary technology leverages a natural, known mechanism in the body to regular cell growth. It works by inhibiting the growth of cancer cells.

Ordinatrix LLC, provides research and development tools that aid in the development of new drugs, diagnosis of disease and approaches to personalized medicine. The company is an innovation spinoff from Arizona State University. It creates or “prints” protein microarrays based on DNA. The protein arrays deliver more functional, flexible and precise options for researchers.

Investor judges attend the presentations, pepper company executives with questions. The judges seek answers demonstrating the company has the scientific, human resource and business acumen to succeed. After sessions, judges provide feedback for the finalists. While any of the 40 presenting companies can find strategic partners, grant opportunities or venture investors, five companies designated as the winners receive other key benefits for fuel getting products to approval and market.

To be considered qualified to take the stage at the stadium, companies cannot have raised more than $10 million since inception and employ fewer than 20 full-time employees. The firms must have made a previous business pitch or participated in a capital competition. No previous experience in BIO partnering is permitted.

3 Arizona startups compete in international bioscience competition​

A startup CEO standing on a stage makes a presentation to five judges sitting at a table during an eventChief Science Officer Dan Mahaffey presents the Humabiologics story at the BIO International 2019 Startup Stadium. Three Phoenix bioscience startups are finalists in 2020. Photo credit: Humabiologics

​JUNE 11, 2020 3:30 PM

Pamela Turbeville only has six minutes to pitch a product she spent six years working on. 

If her pitch is successful, she could land meetings with big-name investors at one of the largest bioscience conferences globally.

By Amanda Morris for The Arizona Republic

She is one of 30 finalists competing at this year's Bio International Startup Stadium contest, which helps to launch early-stage bioscience companies.

In this year's virtual competition, judges will review six-minute pitch videos submitted by each finalist and select several winners.

Each competitor must be a small bioscience startup that has less than 20 employees. The idea, said Nareg Sagherian, a Bio International managing director, is to spotlight promising young companies that might otherwise be overlooked at a large international conference.


Read the full story at AZCentral​


​​​